Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Psychiatric Rehabilitation 5Melphalan 5Cyclophosphamide 5Methylprednisolone 4Flow Cytometry 4Busulfan 4Early Intervention, Educational 3Antilymphocyte Serum 3Alemtuzumab 3fludarabine phosphate 2Radiotherapy 2Immunologic Techniques 2Filgrastim 2Azacitidine 2thymoglobulin 1tanespimycin 1sargramostim 1ruxolitinib 1rucaparib 1pembrolizumab 1neratinib 1ixabepilone 1fosphenytoin 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1bempegaldesleukin 1aldesleukin 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Fenofibrate × CNS × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡